is.......................Broke and can't be fixed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Red, Is that in Key West?
Is that your dinghy Red?
18
48
99
Good luck to all!
Picked up TLON at $1.15
Fact number one.
Company lost $2.5 million last quarter.
Fact number two.
Company lost $2.3 million one year ago, same quarter.
If anyone would like to debate the facts, I'm more than willing to have an intelligent back and forth.
It certainly does not look like a reversal is coming any time soon. This is an orchestrated sell off. Drifting lower and lower all day long.
I guess the market has spoken as far as the earnings report goes. This company lost about the same amount of money it lost previous year for the same quarter.
USAT announced earnings today. More losses keep piling up. This is not a sustainable business model. They have lost money for 19 straight years and counting. The company has never turned a profit, not even one quarter.
Be careful with this company the ceo runs it like his own personal ATM.
DEPO
MENLO PARK, Calif., May 10, 2011 -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has received a Paragraph IV certification notice from Sun Pharmaceutical Industries advising Depomed that Sun has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Glumetza® (metformin hydrochloride extended release tablets), 500 mg and 1000 mg strengths. Sun's certification notice alleges that the five U.S. Patents listed in the FDA Orange Book for Glumetza, with expiration dates ranging from 2016 to 2025, will not be infringed by Sun's proposed product, or are invalid and/or are unenforceable.
Depomed is evaluating the Paragraph IV certification, and intends to vigorously enforce its intellectual property rights. Depomed has 45 days from the receipt of the Paragraph IV certification to commence a patent infringement lawsuit against Sun that would automatically stay, or bar, the FDA from approving Sun's ANDA for 30 months or until a district court decision that is adverse to the company, whichever is earlier.
The notice from Sun is the second Paragraph IV certification notice received for Glumetza. In November 2009, Depomed initiated its ongoing patent infringement lawsuit against Lupin Limited in connection with Lupin's ANDA seeking approval to market a generic version of Glumetza®.
New FINRA Rules 6460 on May 9 2011
Categories: Rules
Of the 3 new rules kicking in on Monday 5/9/11 FINRA 6460 is the one to concentrate on. My legal buddies are referring to it as the “new leap frog rule”. MMs now have to show the full size of any orders that are the high bid or low offer. Before they could hide a large buy order by only showing 5,000 shares of it which was and is the minimum for penny stocks. The key concept here is “forced transparency”. From now on if a “whale” shows a bid for 10 million shares of XXX and it is higher than the previous bid then the MM must either reflect it or jump it by a notch to hide it. The “whale” would then need to jump it to get it to be the high bid. Hence the term leap frog.
If an abusive MM with an enormous preexisting naked short position puts in a large offer to scare buyers aware then he has to place it below the former offer and he’s going to have to honor that sale if the “whale” chooses to take him out. The “whales” are going to get pretty ticked off if the MM representing his order fraudulently makes him pay higher because of his antics needing to be performed to hide the large order. This might violate the “best execution rule” (NASD 2320) wherein a broker has a formal “duty” to find the best market to aim an order towards.
“Whales” want to buy size but a crooked MM sitting on a monstrous naked short position with the fear that XXX just might “have the goods” does not want to sell size. He just wants to fraudulently induce selling and dissuade buying. A variety of the “3Ms” (“market maker manipulations”) are going to be rendered moot. As you can well imagine, a crime as obvious as selling nonexistent shares all day long while pretending to be “injecting liquidity” needs to be done in an environment with no transparency. “Leap frogging” is going to look very, very obvious on a time and sales sheet! There is no better disinfectant than the light of day.
6460. Display of Customer Limit Orders
This version of the rule (or interpretive material) does not become effective until May 9 2011.
(a) Each OTC Market Maker displaying a priced quotation in any OTC Equity Security in an inter-dealer quotation system shall publish immediately a bid or offer that reflects:
(1) The price and the full size of each customer limit order held by the OTC Market Maker that is at a price that would improve the bid or offer of such OTC Market Maker in such security; and
(2) The full size of each customer limit order held by the OTC Market Maker that:
(A) Is priced equal to the bid or offer of such OTC Market Maker for such security;
(B) Is priced equal to the best bid or best offer of the inter-dealer quotation system in which the OTC Market Maker is quoting; and
(C) Represents more than a de minimis change in relation to the size associated with the OTC Market Maker's bid or offer.
(b) The requirements in paragraph (a) of this Rule shall not apply to any customer limit order:
(1) That is executed upon receipt of the order.
(2) That is placed by a customer who expressly requests, either at the time that the order is placed or prior thereto pursuant to an individually negotiated agreement with respect to such customer's orders, that the order not be displayed.
(3) That is an odd-lot order.
(4) That is a block size order, unless a customer placing such order requests that the order be displayed.
(5) That is delivered immediately upon receipt to a national securities exchange or an electronic communications network that widely disseminates such order and that complies with paragraph (c) below with respect to that order.
(6) That is delivered immediately upon receipt to another OTC Market Maker that complies with the requirements of this Rule with respect to that order.
(7) That is an all-or-none order.
(8) That is priced less than $0.0001 per share.
(c) The electronic communications network:
(1) Provides to a national securities exchange, national securities association or inter-dealer quotation system the prices and sizes of the orders at the highest buy price and the lowest sell price for such security entered in, and widely disseminated by, the electronic communications network; and
(2) Provides, to any broker or dealer, the ability to effect a transaction with a priced order widely disseminated by the electronic communications network entered therein by an OTC market maker that is:
(A) Equivalent to the ability of any broker or dealer to effect a transaction with an OTC market maker pursuant to the rules of the applicable national securities exchange, national securities association or inter-dealer quotation system to which the electronic communications network supplies such bids and offers; and
(B) At the price of the highest priced buy order or lowest priced sell order, or better, for the lesser of the cumulative size of such priced orders entered therein by OTC market makers at such price, or the size of the execution sought by the broker or dealer, for such security.
(d) Definitions
For purposes of this Rule, the following definitions shall apply:
(1) Best bid and best offer mean the highest priced bid and the lowest priced offer.
(2) Block size with respect to an order means it is of at least 10,000 shares and has a market value of at least $100,000.
(3) Customer limit order means an order to buy or sell an OTC Equity Security at a specified price that is not for the account of either a broker or dealer; provided, however, that the term customer limit order shall include an order transmitted by a broker or dealer on behalf of a customer.
TLON
Stock Offering but not by the company.
USE OF PROCEEDS
We will receive none of the proceeds from the sale of the shares by the selling stockholders. Certain of the shares offered hereby are issuable upon the exercise of outstanding warrants. Upon exercise of such warrants we will receive the applicable exercise price paid by the holders of the warrants.
SELLING STOCKHOLDERS
This prospectus covers the resale by the selling stockholders identified below of 6,414,027 shares of common stock, as follows:
·
5,622,296 shares that were originally issued in our October 2009 private placement, including 1,982,428 shares issuable upon on the exercise of warrants issued in such private placement and that remain outstanding;
·
737,383 shares of our common stock purchased in open market transactions by Deerfield Special Situations Fund International Limited and Deerfield Special Situations Fund, L.P. prior to October 2007; and
·
54,348 shares issuable upon exercise of a warrant, at an exercise price of $0.92 per share, that we issued to a financial advisor in 2010 for services rendered.
http://ir.talontx.com/secfiling.cfm?filingID=1144204-11-26480&CIK=1140028
Thank you sir!
Whenever I feel good about my picks, well......you know, a bump here and a bump there.
11
18
99
For now at least.
SPPI conference call.
NO need to raise capital.
Raj repeated that there will be no need to raise capital.
pps up to $8.54 from LOD of $7.88
How about the 1 for 100 R/S?
This company has had a history of losing money and it has always been the shareholder's money. Insiders have purchased next to none of this stock, and also have sold nearly all the stock they were awarded. At least all the shares they can sell.
19 straight years of losing money.
Over $190 Million dollars.
CEO has gotten rich during this.
No predictions of profit.
All this may change, but right now it's looking like the same ole, same ole.
SPPI getting spanked.
Approval followed by record earnings and it's dropped from the high of $10.50 after approval to a low of $7.88 today.
AVNR
Release #:958-93249-rl-744145:
Avanir Pharmaceuticals Announces Landmark 'PRISM' Pseudobulbar Affect Patient Registry
Registry will Assess Relationship between PBA and Quality of Life
ALISO VIEJO, Calif., May 4, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.(Nasdaq: AVNR) today announced the PRISM patient registry, the first patient registry to further quantify the prevalence and quality of life impact of pseudobulbar affect (PBA) in patients with a variety of underlying neurologic conditions. Nearly two million Americans with existing neurologic disease or brain injury are estimated to be living with the added burden of PBA, a condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or are incongruent to the patient's underlying emotional state. Until now, the complexity of those distinct conditions has served as a barrier to widespread collaboration among treating physicians.
The PRISM registry aims to define the prevalence of PBA in patients with the associated underlying neurologic conditions of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, traumatic brain injury (TBI), and Alzheimer's disease. Avanir anticipates recruiting 10,000 patients into the registry across approximately 500 sites in the U.S. Avanir is working with Novella Clinical as the company's contract research organization and expects enrollment to initiate in May and continue for at least six months. Data collected through PRISM will serve as the basis for continued clinical research efforts surrounding PBA.
"The PRISM registry will assess the relationship between PBA and quality of life among affected patients," said Randall Kaye, M.D., chief medical officer of Avanir. "In addition, data collected across multiple sites in the U.S. will allow participating investigators to compare the incidence of PBA within their practice to regional and national numbers. At Avanir, we believe a better understanding of PBA prevalence is positive for physicians, patients, and caregivers alike, and are thrilled to initiate what will ultimately be the largest PBA clinical registry ever performed."
"As a physician working directly with patients impacted by various neurological conditions and PBA, the PRISM registry represents a tremendous step forward in helping to document the true impact of this misunderstood and under-diagnosed condition," said Jonathan Fellus, M.D., medical director of rehabilitation, Meadowlands Hospital Rehabilitation Institute in New Jersey. "For too long, patients and their families have battled involuntary, sudden, and frequent episodes of laughing and/or crying without the knowledge and comfort that this condition is a treatable condition that many other patients are living with and managing on a daily basis."
About PBA
Patients suffering from existing neurologic disease or brain injury may also suffer the added burden of pseudobulbar affect, or PBA. PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. PBA outbursts result from a "short circuit" in the brain caused by another neurologic condition-such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, or traumatic brain injury. PBA can have a debilitating impact on the lives of patients, caregivers and loved ones. For more information about PBA, please visit www.PBAinfo.org.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.
About Novella Clinical
Novella Clinical, Inc. is a full service contract research organization headquartered in Research Triangle Park, N.C. For more than a decade, Novella has served as an active partner to the oncology, biopharma and medical device industries. As the first global eCRO, Novella integrates deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. For more information, visit www.novellaclinical.com.
AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc.
©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the launch of a registry study are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the ability to enroll clinical sites, the ability to enroll patients into the registry, the ability to define the prevalence of PBA, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
SOURCE Avanir Pharmaceuticals, Inc.
MY AVNR
Market Data
More Information
Wednesday, May 04, 2011 9:15:57 AM 744145
Good luck. I hope it works out well for you. Earnings coming up should tell a lot about this one.
Are you aware of the history of this company?
19+ years of losing money. Dilution of shares followed by big reverse splits, followed by more dilution. CEO taking HUGE money out of the company. I could go on but I won't.
Trade this thing all you want, but I'd never consider it a long term hold. JMO
AVNR just broke through $4.5
The article from AF was not negative for the chances of approval, it was negative for long term profitability of the drug.
He does have a way of creating a stir when he writes an article.
Out of SPPI @ $9.6
I'm in for the bounce, tried @ $8.6 but didn't get any until $8.9
What's with sppi it just dropped $2 ?
18
48
88
And if 888 races I'll take that one too.
BnB, for me it's a matter of picking when I tthink of it. My simple mind can keep a thought for more than a minute, let alone a couple of days.
So when I think of it I pick, mostly ignoring the qualifying anyway even when I pick late.
AVNR
A biased view, very bullish for AVNR from seeking alpha.
http://seekingalpha.com/article/265249-avanir-pharma-begins-to-demonstrate-its-relevance-shares-surge-on-heavy-volume
BMOD???? Wrong board?
Thursday could have been the beginning of a short squeeze. Pre-Market, over 125k shares, could signal more of the same today. The last numbers I saw put the shorts at over 30 million.
CC with scrip numbers coming.
For the Bunny Trail 500.
I'll take in order
The Tooth Fairy in the 25
The Great Pumpkin in the 0
And The Lucky Charms Leprechan in the 7
I'll be expecting the 1,2,3 bonus points this week.
Their site has been down all day. Just adds to the rumors.
I don't give those posted scrip numbers much thought. The service that AF got his numbers from doesn't seem to count a couple of major players in the pharmacy industry. I don't know whether they estimate the numbers from those players, or just ignore them.
You are definetly right about "only mgmt knows for sure".
Over 15 million shares right now, huge volume day.
And the board does it the right way. Just post information available to everyone who wants to track it down.
AVNR broke the $4.14 resistance for a bit here, a close above it would be big.
AVNR does seem to have bounced off the resistance @ $4.14
May just be a run, if it breaks $4.14 it could be something is up.
AVNR
No news that I'm aware of. Just nonsense rumors of a buyout, but they've been around for quite a while. It could be a lot of different things and any guessing on my part would be just that, a guess.
avnr
AVNR hod $4.14 over 12 million shares.
7 Ham sammiches?????????
Did Wrinks go on a diet?
Please update my picks.
18 - 48 - 88
here's hoping 8's are wild.
I can't believe I'm doing this, but..........
18 - 29 - 88
No guts, not glory, aint' that right???? right? maybe?